Imaging of Solid Tumors Using FAP-2286

Launched by THOMAS HOPE · Nov 3, 2020

Keywords

ClinConnect Summary

This clinical trial, called "Imaging of Solid Tumors Using FAP-2286," is studying a new way to detect metastatic cancer in adults with solid tumors. Researchers are testing a special imaging agent called FAP-2286, which helps find cancer by targeting a specific protein found on cancer-related cells. The goal is to see how well this imaging technique works with different types of solid tumors, including breast, pancreatic, prostate, bladder, and colon cancers.

To participate in the trial, you need to be at least 18 years old and have a confirmed diagnosis of a solid tumor. There are different groups in the study, some requiring measurable disease while others do not. If you join, you can expect to undergo imaging tests using the new agent, which could help doctors understand your cancer better and plan your treatment accordingly. It's important to know that women who are pregnant or individuals who may not be able to follow the study rules may not be eligible. If you're interested, be sure to discuss this opportunity with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \>= 18 years
• 2. Histopathologically confirmed solid tumors in one of the following cohorts:
• • a. Cohort 1 (n=16): measurable disease is not required for this cohort. i. Agnostic to tumor type. b. Cohort 2 (n=40): Metastatic disease present on conventional imaging defined as having RECIST 1.1 measurable disease or multiple bone metastases.
• • i. Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, or colon cancer.
• • ii. Pathologically confirmed cancer other than noted above (basket subgroup, n=10).
• • c. Cohort 3 (n=30): No evidence of metastatic disease as defined as the absence of RECIST 1.1 measurable disease or bone metastases.
• • i. Patients can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Patients may also be imaged after definitive therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and/or prognosis.
• • ii. Pathologically confirmed head and neck cancer or bladder cancer.
• • 3. Ability to understand a written informed consent document, and the willingness to sign it.
• Exclusion Criteria:
• • 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
• • 2. Known pregnancy.